Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Autism Spectrum Disorders
NCT01788072Phase 2Completed
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Start
- Jun 2014
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Holland Bloorview Kids Rehabilitation Hospital. Primary endpoint: Social function at 12 weeks. Started Jun 2014; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01788072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788072.